TW202126290A - 腎功能改善用組合物 - Google Patents
腎功能改善用組合物 Download PDFInfo
- Publication number
- TW202126290A TW202126290A TW109132697A TW109132697A TW202126290A TW 202126290 A TW202126290 A TW 202126290A TW 109132697 A TW109132697 A TW 109132697A TW 109132697 A TW109132697 A TW 109132697A TW 202126290 A TW202126290 A TW 202126290A
- Authority
- TW
- Taiwan
- Prior art keywords
- renal function
- composition
- improving
- glycine
- tryptophan
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 230000003907 kidney function Effects 0.000 title claims abstract description 85
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 102
- 239000004471 Glycine Substances 0.000 claims abstract description 49
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 48
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 44
- 235000013305 food Nutrition 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 18
- 102000012192 Cystatin C Human genes 0.000 claims description 12
- 108010061642 Cystatin C Proteins 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 229940109239 creatinine Drugs 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229960002449 glycine Drugs 0.000 description 45
- 229960004799 tryptophan Drugs 0.000 description 42
- 230000037406 food intake Effects 0.000 description 30
- 235000013361 beverage Nutrition 0.000 description 24
- 238000000034 method Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 13
- 239000004375 Dextrin Substances 0.000 description 12
- 229920001353 Dextrin Polymers 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 235000019425 dextrin Nutrition 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 208000020832 chronic kidney disease Diseases 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- -1 inorganic acid salts Chemical class 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 235000004554 glutamine Nutrition 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229960003624 creatine Drugs 0.000 description 5
- 239000006046 creatine Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MBDOYVRWFFCFHM-UHFFFAOYSA-N 2-hexenal Chemical compound CCCC=CC=O MBDOYVRWFFCFHM-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000010630 cinnamon oil Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- RUMOYJJNUMEFDD-UHFFFAOYSA-N perillyl aldehyde Chemical compound CC(=C)C1CCC(C=O)=CC1 RUMOYJJNUMEFDD-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- GHBSPIPJMLAMEP-SECBINFHSA-N (6r)-6-pentyloxan-2-one Chemical compound CCCCC[C@@H]1CCCC(=O)O1 GHBSPIPJMLAMEP-SECBINFHSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- ZFFTZDQKIXPDAF-UHFFFAOYSA-N 2-Furanmethanethiol Chemical compound SCC1=CC=CO1 ZFFTZDQKIXPDAF-UHFFFAOYSA-N 0.000 description 1
- MBDOYVRWFFCFHM-SNAWJCMRSA-N 2-Hexenal Natural products CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 1
- RCSBILYQLVXLJG-UHFFFAOYSA-N 2-Propenyl hexanoate Chemical compound CCCCCC(=O)OCC=C RCSBILYQLVXLJG-UHFFFAOYSA-N 0.000 description 1
- KYNMONSTYCGIDJ-UHFFFAOYSA-N 2-amino-3-(1h-indol-2-yl)propanoic acid Chemical compound C1=CC=C2NC(CC(N)C(O)=O)=CC2=C1 KYNMONSTYCGIDJ-UHFFFAOYSA-N 0.000 description 1
- CFAKWWQIUFSQFU-UHFFFAOYSA-N 2-hydroxy-3-methylcyclopent-2-en-1-one Chemical compound CC1=C(O)C(=O)CC1 CFAKWWQIUFSQFU-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000007129 Cuminum cyminum Nutrition 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- GOMAKLPNAAZVCJ-UHFFFAOYSA-N Ethyl phenylglycidate Chemical compound CCOC(=O)C1OC1C1=CC=CC=C1 GOMAKLPNAAZVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- UZFLPKAIBPNNCA-UHFFFAOYSA-N alpha-ionone Natural products CC(=O)C=CC1C(C)=CCCC1(C)C UZFLPKAIBPNNCA-UHFFFAOYSA-N 0.000 description 1
- UZFLPKAIBPNNCA-BQYQJAHWSA-N alpha-ionone Chemical compound CC(=O)\C=C\C1C(C)=CCCC1(C)C UZFLPKAIBPNNCA-BQYQJAHWSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 235000020152 coffee milk drink Nutrition 0.000 description 1
- 239000010635 coffee oil Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000001072 coriandrum sativum l. fruit oil Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000010644 fenugreek oil Substances 0.000 description 1
- 235000021121 fermented vegetables Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- OALYTRUKMRCXNH-QMMMGPOBSA-N gamma-nonanolactone Chemical compound CCCCC[C@H]1CCC(=O)O1 OALYTRUKMRCXNH-QMMMGPOBSA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000010649 ginger oil Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- UFLHIIWVXFIJGU-UHFFFAOYSA-N hex-3-en-1-ol Natural products CCC=CCCO UFLHIIWVXFIJGU-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 235000020733 paullinia cupana extract Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000001622 pimenta officinalis fruit oil Substances 0.000 description 1
- 239000010465 pomace olive oil Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001327 prunus amygdalus amara l. extract Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011497 sour milk drink Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- PHXATPHONSXBIL-UHFFFAOYSA-N xi-gamma-Undecalactone Chemical compound CCCCCCCC1CCC(=O)O1 PHXATPHONSXBIL-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本發明提供一種改善腎功能之組合物。本發明之腎功能改善用組合物包含甘胺酸與色胺酸，且甘胺酸相對於色胺酸之含有比以質量基準計超過10且未達60。
Description
本發明係關於一種腎功能改善用組合物。
腎臟疾病係因腎臟之絲球體、腎小管等之功能下降而導致腎臟之作用變差之疾病。又，已知腎臟功能會隨著年齡增加而逐漸下降。當腎臟之絲球體之一部分之功能下降時，其他絲球體會彌補其功能，但考慮到絲球體會隨著年齡增加而逐漸減少，因此腎臟功能會下降。若腎臟功能一旦喪失則多數情況下無法恢復，並且有陷入被稱為慢性腎功能衰竭之病況之風險。若腎臟之功能進一步下降並發展為末期腎功能衰竭，成為無法期待腎功能恢復之狀態，則將接受透析療法、腎移植等治療。
表現為腎功能下降、腎臟損傷之慢性腎臟疾病(CKD：chronic kidney disease)係末期腎功能衰竭、心血管疾病之風險因素，在日本，據說有約13%成人、1,330萬人為CKD患者。因此，迫切需要能夠維持/改善腎功能之技術。例如，於國際專利公開2017/002895號中，提出一種包含胺基酸及環狀二肽之具有血管收縮素轉化酶抑制活性之組合物，其具有腎功能保護作用。又，於日本專利特開2002-275059號公報中，提出一種包含特定胺基酸之腎功能損傷改善用胺基酸組合物。
[發明所欲解決之問題]
本發明之目的在於提供一種改善腎功能之組合物。
[解決問題之技術手段]
本發明提供一種腎功能改善用組合物，其包含甘胺酸與色胺酸，且甘胺酸相對於色胺酸之含有比以質量基準計超過10且未達60。
於某一形態中，上述組合物之甘胺酸之攝取量為每次1 g以上10 g以下。
又，本發明提供一種包含上述組合物之腎功能改善用飲食物。
又，本發明提供一種包含上述組合物之腎功能改善用劑。
進而，本發明提供一種腎功能之維持方法及腎功能之改善方法，其包括向對象投予腎功能改善用組合物，上述腎功能改善用組合物包含甘胺酸與色胺酸，且甘胺酸相對於色胺酸之含有比以質量基準計超過10且未達60。
[發明之效果]
根據本發明，可提供一種改善腎功能之組合物。
於本說明書中，於在組合物中存在複數種與各成分相當之物質之情形時，只要無特別說明，則組合物中之各成分之含量意指組合物中所存在之該複數種物質之合計量。
＜腎功能改善用組合物＞
腎功能改善用組合物(以下，亦簡稱為「組合物」)包含甘胺酸與色胺酸作為有效成分，亦可視需要進而包含其他成分。腎功能改善用組合物之甘胺酸相對於色胺酸之含有比以質量基準計超過10且未達60。甘胺酸及色胺酸中之任一者對於腎功能之作用均未知。然而，藉由將甘胺酸與色胺酸以特定之質量比率加以組合而進行攝取，則可維持/改善動物之腎功能。
於本說明書中，腎功能之維持/改善包括維持正常之腎功能及改善已下降之腎功能中之至少一種，例如意指：將評價腎功能之指標維持為正常狀態，改善由於某種因素而惡化之評價腎功能指標以使其接近健康狀態等。作為評價腎功能之指標，例如可列舉：絲球體過濾量(GFR：glomerular filtration rate)、尿蛋白量、尿白蛋白量、血清肌酸酐濃度、血清胱抑素C濃度等。關於維持/改善腎功能之作用，針對評價腎功能之指標，可藉由將投予群與對照群進行比較而確認。又，作為使評價腎功能之指標惡化之要因，例如可列舉：年齡增加、喝酒、吸菸等生活習慣，糖尿病、高血壓等疾病、功能損傷等。
因此，腎功能改善用組合物亦可為選自由GFR、尿蛋白量、尿白蛋白量、血清肌酸酐濃度及血清胱抑素C濃度所組成之群中之至少1種評價腎功能之指標的維持/改善劑。
評價腎功能之指標中之GFR係與提示腎損傷之表現(尿檢異常、影像學異常、血液異常、病理表現等)一起用於CKD診斷的重要指標。於日常診療中，GFR通常被評價為根據血清肌酸之測定值所計算之推算GFR(eGFR)。已知血清肌酸受到肌肉量、性別、年齡等之影響，藉由考慮這些因素之推算式而計算eGFR。此處，本實施方式之腎功能改善用組合物包含甘胺酸作為有效成分之一。已知甘胺酸於生物體內轉換成肌酸(例如，參照J. Anim. Sci. 1991. 69:1532-1550.)。因此，推測由於攝取本實施方式之腎功能改善用組合物而使血清肌酸濃度受到影響，其結果是GFR之評價受到影響。另一方面，血清胱抑素C作為一種新的GFR指標而受到關注。由於血清胱抑素C值不易受到肌肉量、食物、運動等之影響，故而於難以藉由血清肌酸值之GFR推算式進行評價之情形時較為有用(例如，參照CKD診療指南2012)。因此，於本說明書中，基於血清胱抑素C濃度計算eGFR以評價腎功能。因此，腎功能改善用組合物可為GFR之維持/改善劑、eGFR之維持/改善劑、或基於血清胱抑素C濃度之eGFR之維持/改善劑。
組合物中所含之甘胺酸為胺基乙酸，於胺基酸之中具有最單純之結構。甘胺酸之純度只要適合動物攝取即可，其純度例如為90%以上，較佳為98%以上。甘胺酸可藉由例如提取法、微生物醱酵法等而製造，亦可自市售品適當選擇。
色胺酸為2-胺基-3-吲哚基丙酸，只要至少包含L-色胺酸即可。色胺酸亦可為外消旋體，較佳為L-色胺酸。色胺酸之純度只要適合動物攝取即可，其純度例如為90%以上，較佳為98%以上。色胺酸可藉由例如提取法、微生物醱酵法等而製造，亦可自市售品適當選擇。
甘胺酸及色胺酸亦可作為單獨成分(游離體)而被包含，亦可以鹽之形態而被包含。作為甘胺酸及色胺酸之鹽，只要為藥理學上所容許之鹽則無特別限制。具體而言，例如可列舉：酸加成鹽、金屬鹽、銨鹽、有機胺加成鹽等。作為酸加成鹽，可列舉：鹽酸鹽、硫酸鹽、硝酸鹽、磷酸鹽等無機酸鹽，乙酸鹽、順丁烯二酸鹽、反丁烯二酸鹽、檸檬酸鹽、蘋果酸鹽、乳酸鹽、α-酮戊二酸鹽、葡萄糖酸鹽、辛酸鹽等有機酸鹽。作為金屬鹽，可列舉：鈉鹽、鉀鹽等鹼金屬鹽，鎂鹽、鈣鹽等鹼土類金屬鹽，鋁鹽、鋅鹽等。作為銨鹽，可列舉：銨、四甲基銨等鹽。作為有機胺加成鹽，可列舉：𠰌啉、哌啶等鹽。
就腎功能改善作用之觀點而言，組合物中之甘胺酸相對於色胺酸之質量基準之含有比例如超過10且未達60，較佳為12以上45以下，更佳為13以上40以下，進而較佳為14以上35以下。甘胺酸相對於色胺酸之質量基準之含有比例如亦可超過10，較佳為12以上、13以上或14以上。又，甘胺酸相對於色胺酸之質量基準之含有比例如可未達60，較佳為45以下、40以下或35以下。
組合物除了包含甘胺酸及色胺酸以外，亦可進而包含其他有效成分。其他有效成分只要具有維持/改善腎功能之作用即可。作為其他有效成分，例如可列舉：丙胺酸、精胺酸、天冬醯胺、天冬胺酸、半胱胺酸、麩醯胺、麩胺酸、組胺酸、異白胺酸、白胺酸、離胺酸、甲硫胺酸、苯丙胺酸、脯胺酸、絲胺酸、蘇胺酸、酪胺酸、纈胺酸、鳥胺酸、瓜胺酸等其他胺基酸。其他有效成分亦可為選自由除了其等以外之胺基酸所組成之群中之至少1種。其他胺基酸中，較佳為選自由天冬胺酸、天冬醯胺、麩胺酸及麩醯胺所組成之群中之至少1種，更佳為選自由天冬醯胺、麩胺酸及麩醯胺所組成之群中之至少1種，進而較佳為選自由天冬醯胺及麩胺酸所組成之群中之至少1種。其他胺基酸可為1種，亦可為2種以上之組合。
組合物亦可為實質上不含除了甘胺酸與色胺酸以外之其他有效成分者。實質上不含其他有效成分意指其他有效成分之含量未達顯示出維持/改善腎功能之作用之量。具體而言，意指其他有效成分之含量例如相對於甘胺酸而言未達10質量%，未達1質量%，未達0.1質量%、或未達0.01質量%。
組合物中之有效成分之總含量可根據由組合物之構成、組合物之攝取所預期之效果等而適當選擇。組合物中之有效成分之總含量例如為0.0001質量%以上，較佳為0.001質量%以上，更佳為0.01質量%以上，進而較佳為0.1質量%以上，尤佳為1質量%以上、或5質量%以上；又，例如為100質量%以下，較佳為70質量%以下，更佳為50質量%以下、或30質量%以下。
組合物亦可視需要進而包含除有效成分以外之其他成分。作為其他成分，可列舉：水等溶劑；包含維生素B群等之各種維生素類；甜味料；香料；著色料；藥理學上所容許之載體、賦形劑、稀釋劑、鹽類、pH值調整劑、螯合劑、緩衝劑等。
組合物可為散劑、顆粒劑、錠劑、膠囊劑、口含劑、糖漿劑、液劑、注射劑等任意劑型。攝取方法可根據組合物之劑型等自通常使用之攝取路徑選擇。作為攝取路徑，例如可列舉：經口投予、經鼻投予、直腸投予、靜脈注射、點滴等。
組合物之攝取量只要是能夠發揮維持/改善腎功能之作用之量即可，通常情況下，甘胺酸之每次之攝取量例如可為1 g以上，較佳為2 g以上，更佳為3 g以上，進而較佳為5 g以上；又，例如可為10 g以下，較佳為8 g以下，更佳為7 g以下。又，通常情況下，色胺酸之每次之攝取量例如可為0.01 g以上，較佳為0.1 g以上，更佳為0.15 g以上；又，例如可為1.0 g以下，較佳為0.6 g以下，更佳為0.5 g以下，進而較佳為0.4 g以下。又，每日攝取次數例如可為1次至3次。組合物之攝取量例如可為每60 kg體重之攝取量，可根據攝取對象之體重等進行適當變更。
組合物可用於藉由腎功能改善作用而改善病況的疾病之預防及/或治療用途。即，腎功能改善用組合物可為應用於改善腎功能之醫藥組合物。作為相關之疾病，例如可列舉：CKD、糖尿病性腎病、腎硬化、急性腎炎等。組合物可作為抑制上述疾病發病之預防藥而發揮功能，及/或亦可作為改善至正常狀態之治療藥而發揮功能。又，組合物可於預防、抑制腎功能下降等用途中使用。此處，腎功能下降包括由於年齡增加、生活習慣、疾病、功能損傷等所引起者。
組合物之攝取對象只要是具有腎功能之脊椎動物即可，可經口或非經口地安全攝取。組合物之攝取對象例如可為人類、小鼠、大鼠、兔、狗、貓等哺乳動物。組合物之攝取對象可為人類，亦可為非人類動物。例如，於作為非人類動物之貓科動物中，高頻率地發現CKD等是其疾病、死亡等之原因。因此，組合物適宜用於改善貓科動物之腎功能。又，組合物可應用於改善健康人類之評價腎功能指標之用途。於健康人類對象中，包括例如尿蛋白及尿白蛋白為正常值且GFR為90 mL/分鐘/1.73 m2
以上或60 mL/分鐘/1.73 m2
以上之人類(例如，參照一般社團法人日本腎臟學會(編)、「循證CKD診療指南2018」、東京醫學社股份有限公司、2018年6月、第3頁)。
於使用組合物作為疾病之預防及/或治療用醫藥之情形時，組合物之攝取量可根據疾病之種類、攝取對象之年齡、性別、體重、症狀程度、或攝取方法等而適當決定。例如，於使投予對象經口攝取之情形時，以如下之方式一日攝取一次至數次：對於人類成人，每日攝取之甘胺酸及色胺酸之合計通常為1 g以上，較佳為3 g以上，更佳為5 g以上；又，例如為10 g以下，較佳為8 g以下，更佳為7 g以下。攝取期間例如可為1日以上，較佳為1週以上，更佳為1個月以上。又，攝取期間例如可為1年以下，較佳為3個月以下。再者，於使用組合物預防疾病之情形時，攝取期間亦可不作特別限制。
於攝取組合物用以預防、抑制腎功能下降等情形時，組合物之攝取量可根據攝取對象之年齡、性別、體重、或攝取方法等而適當決定。例如，於對投予對象經口投予之情形時，以如下之方式一日攝取一次至數次：對於人類成人，每日攝取之甘胺酸及色胺酸之合計通常1 g以上，較佳為3 g以上，更佳為5 g以上；又，例如為10 g以下，較佳為8 g以下，更佳為7 g以下。攝取期間例如為1日以上，較佳為1週以上。又，攝取期間例如可為1年以下，較佳為3個月以下。再者，於攝取組合物用於預防腎功能下降之情形時，攝取期間亦可不作特別限制。
飲食品
飲食品含有上述包含甘胺酸及色胺酸之腎功能改善用組合物。藉由攝取飲食品，可獲得上述組合物之效果。於含有本發明之腎功能改善用組合物之飲食品中，除了健康飲食品、功能性飲食品、患者用飲食品等以外，包含可調配上述腎功能改善用組合物之所有飲食品。其中，特佳為功能性飲食品。「功能性飲食品」意指對生物體具有一定功能性之飲食品，例如包括特定保健用飲食品(包括有條件之特保[特定保健用食品])及包含營養功能飲食品之保健功能飲食品、特殊用途飲食品、營養輔助飲食品、健康輔助飲食品、補品(例如錠劑、包衣錠劑、糖衣藥丸、膠囊及液劑等各種劑型者)及美容飲食品(例如減肥飲食品)等所有所謂健康飲食品。功能性飲食品還包括基於藥典(FAO/WHO聯合食品標準委員會)之食品標準提出的健康聲明(Health claim)所應用之健康飲食品。
上述健康食品等可為通常食品之形狀，亦可為補品之形狀(錠劑、顆粒劑(例如包裝成棒狀之顆粒劑)、細粒劑、片劑、咀嚼片、膠囊(軟膠囊、硬膠囊)等)。
飲食品亦可為具有流動性之飲料。於飲食品為飲料之情形時，飲料中之甘胺酸濃度例如可為0.1 g/100 ml以上，較佳為0.15 g/100 ml以上，更佳為0.2 g/100 ml以上，進而較佳為0.3 g/100 ml以上，尤佳為0.6 g/100 ml以上；又，例如可為10 g/100 ml以下，較佳為8 g/100 ml以下，更佳為7 g/100 ml以下。又，飲料中之色胺酸濃度例如可為0.001 g/100 ml以上，較佳為0.005 g/100 ml以上，更佳為0.02 g/100 ml以上；又，例如可為1.0 g/100 ml以下，較佳為0.6 g/100 ml以下，更佳為0.4 g/100 ml以下。
飲料例如係含有包含甘胺酸及色胺酸之組合物、及水、果汁等液體介質而構成。飲料例如可為綠茶、烏龍茶及紅茶等茶飲料，清涼飲料、果凍飲料、運動飲料、乳製品飲料、碳酸飲料、蔬菜飲料、果汁飲料、醱酵蔬菜飲料、醱酵果汁飲料、醱酵乳飲料(酸乳飲料等)、乳酸菌飲料、乳製品飲料(咖啡牛奶、水果牛奶等)、粉末飲料、可可飲料、酒精飲料等，亦可為包含組合物且以牛奶、純化水等作為液體介質之飲料。
飲料亦可含有甜味料用以調整甜度。甜味料可為糖，作為糖，可列舉：砂糖、葡萄糖、果糖、果寡糖、半乳寡醣等。或者亦可添加阿斯巴甜、糖精等合成甜味料代替糖。
飲料亦可含有酸味料。作為酸味料，例如可列舉：檸檬酸、DL-蘋果酸、L-酒石酸、乳酸、磷酸等。
飲料亦可含有香料。作為香料，例如可列舉：檸檬、萊姆、柳橙等之橘皮油，橙油、草本提取物等。香料可為天然香料，亦可為合成香料。作為天然香料，例如可列舉：大茴香油、當歸油、眾香子油、橙油、肉桂油、辣椒油、瓜拉那提取物、小豆蔻油、葛縷子油、小茴香油、香紫蘇油、葡萄柚油、丁香油、芫荽籽油、咖啡油、葡萄渣油、可樂果提取物、錫蘭肉桂油、薑油、百里香油、肉豆蔻油、薄荷油、香草精、苦杏仁油、葫蘆巴油、茴香油、胡椒油、胡椒薄荷油、紫蘇油、香柑油、紅橘油、桉葉油、檸檬油、迷迭香油等。
作為合成香料，例如可列舉：大茴香腦、己酸烯丙酯、乙酸異戊酯、γ-十一碳內酯、乙香草醛、丁酸乙酯、縮水甘油酸乙基苯酯、丁香酚、香葉草醇、雙乙醯、甲基環戊烯醇酮、檸檬醛、桂皮醛、萜品醇、δ-癸內酯、癸醛、壬醛、γ-壬內酯、香草醛、苯乙醇、黃酮醇、糠基硫醇、2-己烯醛、3-己烯醇、向日花香醛、紫蘇醛、苯甲醛、麥芽醇、鄰胺苯甲酸甲酯、水楊酸甲酯、薄荷腦、α-紫羅蘭酮、沉香醇等。
本發明之另一態樣包含一種腎功能之維持方法及腎功能之改善方法，其包括向對象投予包含甘胺酸與色胺酸之腎功能改善用組合物。又，本發明之另一態樣亦包含於腎功能之維持方法或腎功能之改善方法所使用之組合物之製造中使用腎功能改善用組合物之方法、於腎功能之維持方法或腎功能之改善方法中使用腎功能改善用組合物之方法、及腎功能之維持方法或腎功能之改善方法所使用之腎功能改善用組合物。
[實施例]
以下，藉由實施例具體說明本發明，但本發明並不限定於該等實施例。
(實施例1)
將31名健康成人男女作為受驗者，獲取書面知情同意後實施試驗。分別將作為對照之糊精5.2 g(Cont)、或包含甘胺酸3.0 g、色胺酸0.2 g及糊精2.0 g之組合物(GlyTrp)作為試驗品，使受驗者毎日1次地經口攝取，持續6週。於試驗品之攝取前及6週後進行採血，測定血清胱抑素C濃度，並基於該測定結果藉由計算式算出eGFR。於表1中示出eGFR之平均值及標準偏差(括號內)。於表1中一併示出t檢驗之經時變化之有意義差、及與對象群之有意義差之結果。
eGFR＝(104×胱抑素C-1.019
×0.996年齡
)－8
[表1]
| eGFR | t檢驗 | |||
| 攝取前 | 6週後 | 經時變化 | vs對照 | |
| 對照群 | 106(12) | 102(13) | 有意義地下降 (p＝0.004) | - |
| GlyTrp群 | 103(15) | 109(14) | 有意義地上升 (p＜0.001) | 有有意義差 (p＜0.001) |
於對照群中，血清胱抑素C濃度上升，於投予了包含甘胺酸與色胺酸之組合物之群中，發現血清胱抑素C濃度之下降。根據使用計算式計算eGFR所得之表1，於投予了包含甘胺酸與色胺酸之組合物之群中，eGFR隨時間有意義地上升，且與對照群相比，發現eGFR之有意義之上升。特別是於eGFR值未達95之較低之10名受驗者中，於投予了包含甘胺酸與色胺酸之組合物之群中，eGFR自90 mL/分鐘/1.73 m2
變為98mL/分鐘/1.73 m2
，發現更顯著之上升。該現象表示越是腎功能進一步下降之對象，越可以期待包含甘胺酸與色胺酸之組合物的腎功能改善效果。
(實施例2)
將16名健康之成人男性作為受驗者，獲取書面知情同意後實施試驗。準備作為對照之糊精6.4 g(對照群)。又，分別準備包含甘胺酸6.0 g與糊精0.4 g之組合物(Gly)、包含色胺酸0.4 g與糊精6.0 g之組合物(Trp)、及包含甘胺酸6.0 g與色胺酸0.4 g之組合物(GlyTrp(6＋0.4))作為試驗品。將各組合物分別作為試驗品而經口單次攝取。於試驗品之攝取前、自攝取開始1小時後、及2小時後進行採血，測定血清胱抑素C濃度，並基於該測定結果藉由上述計算式算出eGFR。於表2中示出eGFR之平均值及標準偏差(括號內)。於表2中一併示出t檢驗之與對象群之有意義差之結果。
[表2]
| Gly/Trp | eGFR | 與對照群之比較 | |||||
| 攝取前 | 1小時後 | 2小時後 | 攝取前 | 1小時後 | 2小時後 | ||
| 對照群 | - | 114(14) | 117(16) | 116(14) | - | - | - |
| Trp群 | - | 117(14) | 120(14) | 120(14) | 無有意義差 (p＝0.139) | 無有意義差 (p＝0.117) | 無有意義差 (p＝0.055) |
| Gly群 | - | 113(10) | 119(11) | 117(14) | 無有意義差 (p＝0.780) | 無有意義差 (p＝0.531) | 無有意義差 (p＝0.716) |
| GlyTrp群 (6＋0.4) | 15 | 119(11) | 125(10) | 123(11) | 無有意義差 (p＝0.093) | 有有意義差 (p＝0.017) | 有有意義差 (p＝0.024) |
根據表2，可知與對照群相比，於攝取了包含甘胺酸與色胺酸且甘胺酸相對於色胺酸之含有比(Gly/Trp)為15之組合物(GlyTrp(6＋0.4))之群中，eGFR有意義地上升。另一方面，於僅投予甘胺酸(Gly)、或僅投予色胺酸(Trp)之情形時，與對照群相比，於eGFR中並未發現有意義差。
(實施例3)
將6名健康成人男性作為受驗者，獲取書面知情同意後實施試驗。準備作為對照之糊精6.4 g(對照群)。準備包含甘胺酸6.0 g、色胺酸0.2 g及糊精0.2 g之組合物(GlyTrp(6＋0.2))、及包含甘胺酸6.0 g、色胺酸0.1 g及糊精0.3 g之組合物(GlyTrp(6＋0.1))作為試驗品，將採血設在攝取2小時後，除此以外，以與實施例2相同之方式計算eGFR並進行評價。將結果示於表3。
[表3]
| Gly/Trp | eGFR | 與對照群之比較 | |||
| 攝取前 | 2小時後 | 攝取前 | 2小時後 | ||
| 對照群 | - | 122(18) | 124(20) | - | - |
| GlyTrp群 (6＋0.1) | 60 | 124(19) | 129(21) | 無有意義差 (p＝0.615) | 無有意義差 (p＝0.067) |
| GlyTrp群 (6＋0.2) | 30 | 125(14) | 129(20) | 無有意義差 (p＝0.261) | 有有意義差 (p＝0.017) |
(實施例4)
將9名健康成人男性作為受驗者，獲取書面知情同意後實施試驗。準備作為對照之糊精6.4 g(對照群)。準備包含甘胺酸2.0 g、色胺酸0.4 g及糊精4.0 g之組合物(GlyTrp(2＋0.4))、包含甘胺酸3.0 g、色胺酸0.4 g及糊精3.0 g之組合物(GlyTrp(3＋0.4))、及包含甘胺酸4.0 g、色胺酸0.4 g及糊精2.0 g之組合物(GlyTrp(4＋0.4))作為試驗品，將採血設在攝取2小時後，除此以外，以與實施例2相同之方式計算eGFR並進行評價。將結果示於表4。
[表4]
| Gly/Trp | eGFR | 與對照群之比較 | |||
| 攝取前 | 2小時後 | 攝取前 | 2小時後 | ||
| 對照群 | - | 120(21) | 124(17) | - | - |
| GlyTrp群 (4＋0.4) | 10 | 118(14) | 120(13) | 無有意義差 (p＝0.212) | 無有意義差 (p＝0.474) |
| GlyTrp群 (3＋0.4) | 7.5 | 120(19) | 124(18) | 無有意義差 (p＝0.934) | 無有意義差 (p＝0.340) |
| GlyTrp群 (2＋0.4) | 5 | 123(17) | 126(19) | 無有意義差 (p＝0.156) | 無有意義差 (p＝0.086) |
如表2至4所示，藉由攝取包含甘胺酸與色胺酸、且甘胺酸相對於色胺酸之含有比在特定範圍內之組合物，使eGFR有意義地提高，從而改善腎功能。
Claims (7)
- 一種腎功能改善用組合物，其包含甘胺酸與色胺酸，且甘胺酸相對於色胺酸之含有比以質量基準計超過10且未達60。
- 如請求項1之腎功能改善用組合物，其中甘胺酸之攝取量為每次1 g以上10 g以下。
- 如請求項1或2之腎功能改善用組合物，其維持或改善選自由絲球體過濾量、尿蛋白量、尿白蛋白量、血清肌酸酐濃度、及血清胱抑素C濃度所組成之群中的至少1種評價腎功能之指標。
- 一種腎功能改善用飲食品，其包含如請求項1至3中任一項之腎功能改善用組合物。
- 一種腎功能維持用飲食品，其包含如請求項1至3中任一項之腎功能改善用組合物。
- 一種腎功能改善劑，其包含如請求項1至3中任一項之腎功能改善用組合物。
- 一種腎功能維持劑，其包含如請求項1至3中任一項之腎功能改善用組合物。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019-173149 | 2019-09-24 | ||
| JP2019173149 | 2019-09-24 | ||
| JP2020-079566 | 2020-04-28 | ||
| JP2020079566 | 2020-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202126290A true TW202126290A (zh) | 2021-07-16 |
Family
ID=75166167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109132697A TW202126290A (zh) | 2019-09-24 | 2020-09-22 | 腎功能改善用組合物 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPWO2021060264A1 (zh) |
| TW (1) | TW202126290A (zh) |
| WO (1) | WO2021060264A1 (zh) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11173143B2 (en) * | 2017-08-30 | 2021-11-16 | Asahi Group Holdings, Ltd. | Composition for decreasing serum uric acid level |
-
2020
- 2020-09-22 TW TW109132697A patent/TW202126290A/zh unknown
- 2020-09-23 JP JP2021548924A patent/JPWO2021060264A1/ja active Pending
- 2020-09-23 WO PCT/JP2020/035768 patent/WO2021060264A1/ja active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021060264A1 (ja) | 2021-04-01 |
| JPWO2021060264A1 (zh) | 2021-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120052138A1 (en) | Composition comprising green tea extract | |
| JP2011098896A (ja) | 尿酸値低下用組成物 | |
| EP3115047B1 (en) | Debility preventative | |
| JP3906716B2 (ja) | 耐糖能異常用薬剤 | |
| JP5939550B2 (ja) | 酸化型アルブミン低下剤 | |
| JP5360368B2 (ja) | 服用感が改善された経口用アミノ酸製剤 | |
| JP5555401B2 (ja) | Ｃ型肝炎ウイルス陽性ヒト肝硬変患者用肝癌発生・進展抑制剤 | |
| JP6492236B1 (ja) | 血清尿酸値低減用組成物 | |
| JP5516654B2 (ja) | 肝癌発生・進展抑制剤 | |
| KR102432193B1 (ko) | 유청단백 가수분해물을 유효성분으로 함유하는 근감소증의 개선, 예방 또는 치료용 조성물 | |
| JP2012031080A (ja) | 二日酔いの症状の回復剤 | |
| EP3133941B1 (en) | Composition for using cinnamaldehyde and zinc for weight management | |
| TW202126290A (zh) | 腎功能改善用組合物 | |
| JP2004161679A (ja) | 内服用液剤 | |
| TWI701031B (zh) | 含有胺基酸及環狀二肽之組成物 | |
| JP5126160B2 (ja) | 耐糖能異常用医薬組成物 | |
| JP2002255801A (ja) | 高血圧予防用組成物 | |
| JP4715423B2 (ja) | 耐糖能異常用医薬組成物及び飲食品 | |
| JP2019043861A (ja) | 乳酸／ピルビン酸比の改善用組成物 | |
| WO2022244867A1 (ja) | 認知機能の改善用組成物、認知機能改善剤および認知機能の改善用食品 | |
| US20220322700A1 (en) | Composition for alleviating, preventing or treating sarcopenia, containing whey protein hydrolysate as active ingredient | |
| JP2019142781A (ja) | 酒酔い対策用組成物 | |
| JP5412708B2 (ja) | 内服用液剤組成物 | |
| JP2020018215A (ja) | 疲労感軽減剤および疲労感軽減用飲食品組成物 | |
| WO2003074039A1 (fr) | Compositions permettant de prevenir l'hypertension |